Table 2.
Characteristics of patients with and without atrial fibrillation recurrence after ablation
| Variables | No recurrence (n = 51) | AF recurrence (n = 25) | p value |
|---|---|---|---|
| Age (years) |
65 ± 9 |
66 ± 8 |
0.728 |
| Gender (male) |
26 (51.0%) |
13 (52.0%) |
0.933 |
| Body mass index (kg/m2) |
25.74 ± 3.46 |
26.13 ± 3.65 |
0.710 |
| Smoking (%) |
21 (41.2%) |
7 (28.0%) |
0.263 |
|
Persistent atrial fibrillation (%) |
14 (27.5%) |
19 (76.0%) |
< 0.001 |
| Duration of atrial fibrillation (months) |
24 ± 5 |
60 ± 15 |
0.090 |
| Comorbidity |
|
|
|
| Hypertension (%) |
26 (51.0%) |
11 (44.0%) |
0.567 |
| Diabetes mellitus (%) |
13 (25.5%) |
9 (36.0%) |
0.343 |
| Coronary artery disease (%) |
5 (9.8%) |
4 (16.0%) |
0.432 |
| Medications |
|
|
|
| Statins |
22 (43.1%) |
12 (48.0%) |
0.689 |
| ACEI/ARB |
40 (78.4%) |
18 (72.0%) |
0.536 |
| Renal function |
|
|
|
| Blood urea nitrogen (mmol/L) |
5.67 ± 1.60 |
5.43 ± 1.87 |
0.630 |
| Creatinine (μmol/L) |
77.58 ± 16.81 |
79.75 ± 8.85 |
0.526 |
| Creatinine clearance (mL/min) |
83.12 ± 28.23 |
79.06 ± 22.86 |
0.616 |
| Echocardiographic data |
|
|
|
|
Left atrial diameter (mm) |
39.0 ± 3.5 |
44.9 ± 2.1 |
< 0.001 |
| Left ventricular end-diastolic diameter (mm) |
46.3 ± 3.9 |
46.9 ± 4.2 |
0.593 |
| Left ventricular end-systolic diameter (mm) |
28.0 ± 3.1 |
27.5 ± 2.1 |
0.411 |
| Left ventricular ejection fraction (%) |
69.0 ± 5.8 |
70.0 ± 3.5 |
0.354 |
|
NT-proBNP (pg/ml) |
204.50 ± 56.35 |
347.80 ± 35.80 |
< 0.001 |
| Ablation protocol (persistent AF) |
n=14 |
n=19 |
|
| CAPV+additional linear ablation |
8 (57.1%) |
9 (47.4%) |
0.728 |
| CAPV+LA "roof" line |
8 (57.1%) |
9 (47.4%) |
0.728 |
| CAPV+LA "mitral isthmus" line |
8 (57.1%) |
9 (47.4%) |
0.728 |
| Ablation protocol (paroxysmal AF) |
n=37 |
n=6 |
|
| CAPV+additional linear ablation |
7 (18.9%) |
2 (33.3%) |
0.589 |
| CAPV+LA "roof" line |
7 (18.9%) |
2 (33.3%) |
0.589 |
| CAPV+LA "mitral isthmus" line | 5 (13.5%) | 0 | - |
Data were expressed as numbers (%), Mean ± SD.
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, NT-proBNP = N-terminal pro-brain natriuretic peptide,CAPV=circumferential ablation of pulmonary vein, LA=left atrium.